Literature DB >> 1934617

X-linked agammaglobulinemia.

E Timmers1, M de Weers, F W Alt, R W Hendriks, R K Schuurman.   

Abstract

X-linked agammaglobulinemia (XLA) patients manifest a very low production of immunoglobulins (Ig) of all classes and plasma cells are virtually absent. The XLA gene plays a crucial role in the transition of pre-B cells to later B cell stages, as hardly any slg-positive B lymphocytes can be detected. In the bone marrow almost normal numbers of pre-B lymphocytes are present. These cytoplasmatic C mu+ pre-B lymphocytes appear to express truncated M heavy chain molecules lacking the variable region segment. The T lymphocyte compartment is intact: the numbers of mature T cell receptor (TcR) alpha beta expressing T lymphocyte populations and their proliferative responses to antigens are normal. That the B cells are primary and exclusively affected was proven by X-chromosome inactivation studies. There is no evidence that the XLA gene is directly involved in the Ig gene rearrangements since B lymphoblastoid cell lines (BLCLs) established from peripheral blood of XLA patients were found to produce IgM molecules composed of complete Ig heavy and light chains and were shown to contain normal VHDJH recombinations. The data do not exclude the involvement of the XLA gene in a B cell specific process that makes the Ig loci accessible for recombination. Investigations on the degree of diversity of immunoglobulins generated by XLA patients exposed no limitations in the VH family usage. Sequence analysis of expressed VH3 and VH4 rearrangements however revealed that some genetic elements of the Ig locus might be over-represented and that a high portion of rearrangements was generated by unconventional mechanisms. By restriction length polymorphism (RFLP) and pulsed field gel electrophoreses analyses the XLA gene was mapped to an 8- to 12-Mb DNA fragment located in the Xq22 region. The known location of the XLA gene on the X-chromosome with closely linked RFLP markers and the availability of X-chromosome inactivation assays provides methods for carrier detection and prenatal diagnosis.

Entities:  

Mesh:

Year:  1991        PMID: 1934617     DOI: 10.1016/s0090-1229(05)80042-x

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  6 in total

1.  Regulation of dendritic cell maturation and function by Bruton's tyrosine kinase via IL-10 and Stat3.

Authors:  Yuko Kawakami; Naoki Inagaki; Shahram Salek-Ardakani; Jiro Kitaura; Hiroyuki Tanaka; Koichi Nagao; Yu Kawakami; Wenbin Xiao; Hiroichi Nagai; Michael Croft; Toshiaki Kawakami
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-21       Impact factor: 11.205

2.  Mapping of the agammaglobulinemia tyrosine kinase gene on the mouse X chromosome with interspecific crosses.

Authors:  R W Hendriks; V Reed; Y Boyd
Journal:  Mamm Genome       Date:  1994-01       Impact factor: 2.957

3.  Bruton's tyrosine kinase defect in dendritic cells from X-linked agammaglobulinaemia patients does not influence their differentiation, maturation and antigen-presenting cell function.

Authors:  M C Gagliardi; A Finocchi; P Orlandi; L Cursi; C Cancrini; V Moschese; T Miyawaki; P Rossi
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

Review 4.  Ibrutinib and novel BTK inhibitors in clinical development.

Authors:  Akintunde Akinleye; Yamei Chen; Nikhil Mukhi; Yongping Song; Delong Liu
Journal:  J Hematol Oncol       Date:  2013-08-19       Impact factor: 17.388

5.  Patient with agammaglobulinemia produces anti-SARS-CoV-2 reactive T-cells after CoronaVac vaccine.

Authors:  Telma Miyuki Oshiro; Lais Teodoro da Silva; Marina Mazzilli Ortega; Sandro Felix Perazzio; Alberto Jose da Silva Duarte; Magda Carneiro-Sampaio
Journal:  Clinics (Sao Paulo)       Date:  2022-02-02       Impact factor: 2.365

6.  COVID-19 Vaccination Responses with Different Vaccine Platforms in Patients with Inborn Errors of Immunity.

Authors:  Lorenzo Erra; Ignacio Uriarte; Liliana Bezrodnik; María Belén Almejun; Ana Colado; María Virginia Paolini; Gisela Seminario; Julieta Belén Fernández; Lorena Tau; Juliana Bernatowiez; Ileana Moreira; Sebastián Vishnopolska; Martín Rumbo; Chiara Cassarino; Gustavo Vijoditz; Ana Laura López; Renata Curciarello; Diego Rodríguez; Gastón Rizzo; Malena Ferreyra; Leila Romina Ferreyra Mufarregue; María Noel Badano; María Inés Pérez Millán; María Florencia Quiroga; Patricia Baré; Itatí Ibañez; Roberto Pozner; Mercedes Borge; Guillermo Docena
Journal:  J Clin Immunol       Date:  2022-10-17       Impact factor: 8.542

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.